Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 86 publications
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 17, 2026
Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+/HER2- metastatic breast cancer.
Journal: Pathologica
Published: July 23, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
Journal: JAMA oncology
Published: May 22, 2025
BRAF mutation and neoadjuvant chemo-immunotherapy, is it worthwhile?
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 14, 2025
A decalogue of Molecular Tumor Board (MTB) recommendations from the CAN.HEAL Consortium.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 25, 2025
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 07, 2025
DESTINY of Immunotherapy in Patients With HER2 Mutant Lung Cancer: Case Report.
Journal: JTO clinical and research reports
Published: November 19, 2024
Kirsten Rat Sarcoma Virus Mutations Effect On Tumor Doubling Time And Prognosis Of Solid Dominant Stage I Lung Adenocarcinoma.
Journal: Clinical lung cancer
Published: September 20, 2024
Last Updated: 09/26/2026